CURIS AND PROCTER & GAMBLE ENTER INTO R&D AGREEMENT FOR HAIR GROWTH PROGRAM

Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that the Company has entered into an exclusive worldwide research and development agreement with Procter & Gamble Pharmaceuticals, a division of The Procter & Gamble Company (NYSE: PG), to evaluate and develop potential treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Future efforts may be expanded to address other skin disorders. To date, Curis scientists have demonstrated that small molecule Hedgehog agonists can induce hair growth in pre-clinical models.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050919005560&newsLang=en)